{
    "name": "mecasermin",
    "comment": "Rx",
    "other_names": [
        "Increlex"
    ],
    "classes": [
        "Growth Hormone Analogs",
        "Insulinlike Growth Factors"
    ],
    "source": "https://reference.medscape.com/drug/increlex-mecasermin-342798",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women; exposure during pregnancy is unlikely because the drug is not indicated for use after epiphyseal closure"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, there were no observed embryo-fetal development abnormalities with intravenous administration to pregnant rats and rabbits during fetal organogenesis given at exposures up to 11 and 3 times maximum recommended human dose (MRHD) of 0.24 mg/kg/day based on body surface area (BSA), respectively"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information available on presence of mecasermin in human or animal milk, effects on breastfed infant, or on milk production; the developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breast-fed child from treatment or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to product or components",
                "Closed epiphyses",
                "Active or suspected neoplasia; discontinue if neoplasia develops",
                "IV administration",
                "Pediatric patients with malignant neoplasia or a history of malignancy"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Do not give without meal/snack 20 min before/after (risk of hypoglycemia)",
                "Not a substitute for GH treatment",
                "Contains benzyl alcohol as preservative (associated with fatal \"Gasping Syndrome\" in preemies)",
                "Possibility of thickening of facial soft tissues",
                "Allergic reactions reported include localized (injection site) reactions to severe systemic reactions, including anaphylaxis requiring hospitalization",
                "Symptoms associated with intracranial hypertension including nausea, headache, papilledema, vomiting, visual changes reported; funduscopic examinations are recommended",
                "Lymphoid hypertrophy that may lead to complications such as chronic middle ear effusions, snoring, and sleep apnea reported",
                "Children experiencing rapid growth may have progression of scoliosis",
                "Caution in patients at risk for diabetes or patients being treated for diabetes",
                "Treat thyroid deficiency prior to therapy",
                "Evaluate any child with onset of a limp or hip/knee pain for possible slipped capital femoral epiphysis",
                "Patients should avoid engaging in high-risk activities (eg, driving, exercise, etc.) within 2 to 3 hours after dosing, particularly during initiation of treatment until tolerability and stable dose established",
                "There have been postmarketing reports of malignant neoplasms in pediatric patients who have received treatment; unknown whether there is relationship between therapy and new occurrence of neoplasia; monitor all patients receiving therapy carefully for development of neoplasms; advise patients/caregivers to report development of new neoplasms; if malignant neoplasia develops, discontinue treatment "
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "macimorelin",
            "description": {
                "common": "mecasermin, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that may blunt the growth hormone (GH) response to macrimorelin may impact the accuracy of the diagnostic test. Discontinue GH products at least 1 week before administering macimorelin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acarbose",
            "description": {
                "common": "mecasermin increases effects of acarbose by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bexagliflozin",
            "description": {
                "common": "mecasermin decreases effects of bexagliflozin by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating growth hormone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "mecasermin increases effects of chlorpropamide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "mecasermin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "mecasermin increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "mecasermin increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "mecasermin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "mecasermin, insulin degludec.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "mecasermin, insulin degludec/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "mecasermin increases effects of insulin detemir by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "mecasermin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "mecasermin increases effects of insulin glulisine by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "mecasermin, insulin inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "mecasermin increases effects of insulin lispro by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "mecasermin increases effects of insulin NPH by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "mecasermin increases effects of insulin regular human by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "mecasermin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miglitol",
            "description": {
                "common": "mecasermin increases effects of miglitol by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "mecasermin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "mecasermin increases effects of pioglitazone by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "mecasermin increases effects of repaglinide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "mecasermin increases effects of rosiglitazone by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "mecasermin increases effects of saxagliptin by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "mecasermin increases effects of sitagliptin by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "mecasermin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "mecasermin increases effects of tolbutamide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vildagliptin",
            "description": {
                "common": "mecasermin increases effects of vildagliptin by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hypoglycemia",
            "percent": "42"
        },
        {
            "name": "Tonsillar hypertrophy",
            "percent": "15"
        },
        {
            "name": "Cardiac murmur",
            "percent": "5"
        },
        {
            "name": "Dizziness",
            "percent": "5"
        },
        {
            "name": "Convulsion",
            "percent": "5"
        },
        {
            "name": "Headache",
            "percent": "5"
        },
        {
            "name": "Lipohypertrophy",
            "percent": "5"
        },
        {
            "name": "Thymus hypertrophy",
            "percent": "5"
        },
        {
            "name": "Arthralgia",
            "percent": "5"
        },
        {
            "name": "Ear problems",
            "percent": "5"
        },
        {
            "name": "Otitis media",
            "percent": "5"
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Generalized urticaria",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Local allergic reactions at the injection site",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "hair texture abnormal",
            "percent": null
        },
        {
            "name": "Systemic hypersensitivity",
            "percent": null
        },
        {
            "name": "anaphylaxis",
            "percent": null
        },
        {
            "name": "generalized urticaria",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "Local allergic reactions at the injection site",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Skin and Subcutaneous Tissue Disorders",
            "percent": null
        },
        {
            "name": "alopecia",
            "percent": null
        },
        {
            "name": "hair texture abnormal",
            "percent": null
        },
        {
            "name": "General disorders and administrative site conditions",
            "percent": null
        },
        {
            "name": "Injection site reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "hematoma",
            "percent": null
        },
        {
            "name": "hemorrhage",
            "percent": null
        },
        {
            "name": "induration",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Osteonecrosis",
            "percent": null
        },
        {
            "name": "avascular necrosis",
            "percent": null
        },
        {
            "name": "occasionally associated with slipped capital femoral epiphysis",
            "percent": null
        },
        {
            "name": "Neoplasms Benign",
            "percent": null
        },
        {
            "name": "Malignant and Unspecified",
            "percent": null
        },
        {
            "name": "including cysts and polyps",
            "percent": null
        }
    ]
}